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Abstract
The behavior and genetics of serous epithelial ovarian cancer (EOC) metastasis, the form of the disease lethal to patients, is
poorly understood. The unique properties of metastases are critical to understand to improve treatments of the disease that
remains in patients after debulking surgery. We sought to identify the genetic and phenotypic landscape of metastatic
progression of EOC to understand how metastases compare to primary tumors. DNA copy number and mRNA expression
differences between matched primary human tumors and omental metastases, collected at the same time during debulking
surgery before chemotherapy, were measured using microarrays. qPCR and immunohistochemistry validated findings.
Pathway analysis of mRNA expression revealed metastatic cancer cells are more proliferative and less apoptotic than
primary tumors, perhaps explaining the aggressive nature of these lesions. Most cases had copy number aberrations (CNAs)
that differed between primary and metastatic tumors, but we did not detect CNAs that are recurrent across cases. A six gene
expression signature distinguishes primary from metastatic tumors and predicts overall survival in independent datasets.
The genetic differences between primary and metastatic tumors, yet common expression changes, suggest that the major
clone in metastases is not the same as in primary tumors, but the cancer cells adapt to the omentum similarly. Together,
these data highlight how ovarian tumors develop into a distinct, more aggressive metastatic state that should be
considered for therapy development.
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Introduction
Serous Epithelial Ovarian Cancer (EOC) is an aggressive
disease for which there are few effective biomarkers and therapies.
EOC is often diagnosed after tumor cells have disseminated within
the peritoneal cavity [1] and metastases account for the majority of
disease-related deaths. Despite its vital role in disease progression,
however, the features required for ovarian cancer metastasis
remain poorly understood [1]. Ovarian tumors do not typically
spread through a hematogenous route, but rather shed from the
primary tumor and enter the peritoneal fluid. Primary ovarian
tumors typically spread within the peritoneal cavity, most often to
the omentum.
The purpose of this study was to identify features that may be
important in establishing metastases. As cancer cells metastasize,
specific cancer cells with distinct genomes and phenotypes may be
selected. Comparing primary and metastatic tumors has generated
important insights into disease progression in both animal models
[2] and in patients [3]. To improve treatment of metastatic
disease, it is vital to understand the genes and pathways expressed
in metastases, as many genes have the potential to contribute to
aggressive phenotypes.
mRNA expression data using early generation microarrays
suggest there are few significant expression differences between
omental lesions and primary tumors [4–6]. However, numerous
studies testing specific functions observe differential expression of
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factors between primary tumors and metastases including MMPs
[7,8] and integrins [9]. Copy number changes, large structural
variants, and point mutations identified by next-generation
sequencing suggest that specific genetic differences are found in
metastases compared to primary tumors from the same patient
[10–13].
We observe significant differences between the primary and
omental metastatic tumors by gene expression microarray analysis.
We found that the copy number alterations that differ between
matched primary and metastatic tumors do not explain the
recurring expression differences that define common features of
metastasis. Up-regulated signaling pathways, including TGFb
signaling, suggest that tumor cells are adapting to the new omental
environment. qPCR and immunohistochemistry support the
microarray findings that metastases appear to be more prolifer-
ative and have less apoptotic cells than primary tumors. We define
a ‘‘metastatic expression signature’’ of the most significantly
differentially expressed genes between primary and metastatic
tumors. This signature identifies poor prognosis patients by
Kaplan-Meier analysis in two large independent primary tumor
datasets. Bootstrapping demonstrates that this six gene signature is
among the top performing of all possible six gene combinations. In
sum, these data suggest that metastatic tumors progress into a
more aggressive state distinct from many primary tumors and may
prove to be more indicative of the disease that needs to be treated.
Materials and Methods
Ethics Statement
Informed consent was obtained from all study participants prior
to study entry by appropriately trained study personnel. After
obtaining written consent, primary ovarian tumor and an omental
metastatic tumor were collected from each de-identified cases
using protocol #08-0095 approved by the Institutional Review
Board of the Women’s and Infants Hospital of Rhode Island.
Patient and Sample Collection
We identified 19 matched primary and omental metastatic
tumor specimens from patients with serous adenocarcinomas
including 14 serous epithelial ovarian, 4 serous epithelial fallopian
tube and one serous epithelial primary peritoneal (Figure S1). All
patients are post-menopausal and had metastatic disease (Table
S1). All patients were over age 55, stage III or later, and all tumors
were chemotherapy-naı¨ve. A pathologist examined all specimens
(MS). Samples were frozen in liquid nitrogen within ten minutes
after extraction. Primary and metastatic tumors were collected
during the same initial debulking surgery before chemotherapy.
Only regions with .70% of cancer cells as determined by
hematoxylin and eosin (H&E) staining were selected for analysis.
RNA isolation and Affymetrix microarrays
Tumor tissue with .70% cancer cells was homogenized with a
Tekmar Tissumizer (Cincinnati, OH). RNA was purified using
miRNeasy kit (Qiagen, Valencia, CA). Nugen WT-Ovation Pico
kit with the WT-Ovation Exon Module was used to prepare the
RNA for Affymetrix Human Gene St v1.0 microarrays following
manufacturer instructions in the Brown University Center for
Genomics and Proteomics core facility. Data were quantile
normalized and signals estimated using Robust Multi-array
Average (RMA). Genes with consistent signal below the lowest
quartile were removed. Data are deposited to the Gene Expression
Omnibus in series GSE30587.
DNA purification and copy number analysis
DNA was isolated using Qiagen DNeasy Blood and Tissue
Kit following manufacturer’s instructions. DNA quality was
determined on an agarose gel. DNA was prepared for Agilent
180K CGH microarrays using the Roche NimbleGen (Madi-
son, WI) enzymatic labeling protocol using random nonamers
and hybridized following manufacturer’s protocols at the
Microarray Centre at the Prostate Centre in Vancouver,
British Columbia, Canada. Each sample was hybridized with
Promega (Madison, WI) female reference DNA. The log10
copy number ratios were smoothed using a standard deviation-
based outlier detection method and segmented using Circular
Binary Segmentation (CBS) [14] as implemented in the R
package DNAcopy (‘smooth.region = 10’ for the smoothing
method, ‘alpha = 0.05’ for the segmentation, and default
parameters for all other arguments). A log10 copy number
for each gene was computed by averaging the smoothed and
segmented log10 ratios for each probe located within the gene
region. Only genes that contained three or more probes were
considered.
Quantitative Real-Time PCR
Equal amounts of total RNA were reverse transcribed using
Superscript III and random hexamers (Invitrogen, Carlsbad, CA).
Resulting cDNA was renormalized using Quant-iT PicoGreen
(Invitrogen) before mixing with Power SYBR Green PCR Master
Mix (Applied Biosystems, Foster City, CA). Reactions were
performed in an Applied Biosystems 7900HT Fast Real-Time
PCR System. Primer sequences are listed in Table S2.
Immunohistochemistry
4 mm slices of formalin fixed paraffin embedded (FFPE)
tissue were prepared from each tumor. Proliferation index was
determined by staining with anti-Ki-67 antibody (Dako, Cat #
IS626). Ki-67 percentage was evaluated manually by compar-
ison with a schematic representation of various percentages of
positive-staining nuclei. Quantification of apoptosis in primary
and metastatic serous epithelial carcinoma was performed with
a Terminal deoxynucleotidyl transferase dUTP Nick End
Labeling assay (TUNEL). Each slice was stained with ApopTag
Plus Peroxidase In Situ Apoptosis Kit (Millipore, Billerica,
MA). Slices were imaged with a Photometrics CoolSNAP
camera (Photometrics, Tucson, AZ) under 106magnification
and assessed for positive apoptosis staining. An apoptotic index
was calculated as the total number of apoptotic cells divided by
the total number of tumor cells from 12 images across each
slice. The distribution of percent apoptotic and Ki-67 cells is
not normal, but is log-normal as determined by a Shapiro-Wilk
test and quantile-quantile plots. Paired t-tests were calculated
after log transformation in R.
Bioinformatics and Survival Analysis
Hierarchical clustering was performed in Gene-E using Pearson
correlation to calculate distances [15]. Survival analysis including
the Cox Proportional Hazards model, Kaplan-Meier analysis, and
statistical tests including Student’s t-test were performed in R. All
TCGA data were downloaded from the TCGA data portal using
the published dataset freeze. All TCGA data include primary
ovarian tumors only. The Australian Oncology Group microarray
data for ovarian tumors, GSE9891, was downloaded from GEO
and processed using RMA.
Ovarian Metastases Differ from Primary Tumors
PLOS ONE | www.plosone.org 2 April 2014 | Volume 9 | Issue 4 | e94476
Ovarian Metastases Differ from Primary Tumors
PLOS ONE | www.plosone.org 3 April 2014 | Volume 9 | Issue 4 | e94476
Results
Identification of Recurring Differentially Expressed Genes
To determine if there are recurring phenotypic changes
between primary and metastatic tumors, we measured the gene
expression profiles in nine of the twelve pairs of primary and
metastatic tumors used for copy number analysis with sufficient
RNA quality for analysis (Table S1A). Three samples had poor
RNA quality and were not considered further for RNA analysis.
77 up-regulated and 10 down-regulated genes between matched
primary and omental tumors have average log2 fold changes .0.9
and q,0.25 in a paired t-test across the cohort (Table S3). The
low number of differentially expressed genes across all cases by
these criteria is similar to past studies [4,6,16] and may be because
of interpatient variation or because of the relatively low sensitivity
of microarrays, or may be because primary and metastatic tumors
are very similar. However, qPCR of genes of interest suggests
significant differential expression for many genes (Figure S2).
Metastatic tumors are more proliferative and anti-
apoptotic
In order to investigate differential expression of pathways
between primary and metastatic tumors, we employed Gene Set
Enrichment Analysis (GSEA) which does not depend on arbitrary
thresholds [17]. We observed higher expression in metastases of
cell communication, cell adhesion, and extracellular matrix
receptor interactions, consistent with expected changes necessary
for colonizing and establishing metastases (Table S4). In primary
tumors, we observe higher expression of cell cycle and DNA repair
factors, suggesting changes in proliferation rates (Table S4, Figure
S3). In particular, GSEA suggests that G2/M checkpoint factors
are more highly expressed in primary tumors compared to
metastases (Figure 1A). We validated the expression levels of a
subset of these genes by qRT-PCR (Figure 1D). We tested this
hypothesis by staining for Ki-67 in each pair of matched tumors
from 19 cases (Figure 1B, 1C and Table S5). These 19 cases
include the 9 tested by microarray and an additional 10 cases
(Table S1C). Ki-67 showed higher staining in metastases in 12/19
cases, including 6/9 of the cases used for expression microarrays,
suggesting that omental metastases are often proliferating more
rapidly than their matched primary tumors (p = 0.01, paired t-
test), at the time of their collection.
To determine which expression changes may originate from
cancer cells, we identified the genes with expression changes that
correlate with the change in Ki-67 immunostaining. We examined
the top 250 genes, all with Pearson correlations .0.72, in DAVID
[18], and observed significant enrichment of cell cycle, M phase,
cell cycle progress, and DNA replication genes (Table S6). This
correlation analysis suggests that many of the cell cycle expression
changes observed by microarray originate from cancer cells and
not tumor infiltrating cells.
Higher expression of pro-survival genes is observed in the
omental lesions including MYC, IRF1, BCL2L2, and TNFSF10
leading to biased expression of the gene ontology anti-apoptosis
gene set as determined by GSEA (Figure 1B). Consistent with
these gene expression changes, decreased TUNEL staining is
observed in 12/15 tested metastases compared to primary tumors,
including 7/9 of the cases measured on the microarrays (p = 0.05,
t-test). Together with the Ki-67 observations (Figure 1A) these data
suggest that cancer cells in metastases are often more proliferative
and may be more inherently resistant to cell death induced by
chemotherapeutics. We conclude that ovarian metastases adapt to
the new omental environment in a more anti-apoptotic and
proliferative state compared to primary tumors.
Expression levels of a number of growth pathways in metastases
compared to primary tumors differ between primary and
metastatic tumors, consistent with increased proliferation and
reduced apoptosis (Table S4). Higher expression of Axin2, DKK2,
NKD1, and NKD2 contribute to enrichment of WNT/b-Catenin
signaling in metastases (Figure S3) consistent with recent studies
[19,20]. Other pathways linked to aggressive cancer include
increased calcium signaling (NES = 2.03, FDR = 0.003), and
increased Jak-Stat, Stat3, and NOTCH signaling in metastases
(Table S4).
Metastatic signature identifies more aggressive tumors
Expression in primary tumors has long been associated with
metastatic potential [1,21]. We hypothesized that transcripts with
significant expression changes to metastases are indicators of
aggressive disease as metastases represent a more advanced stage
of disease. To test this hypothesis, we identified transcripts that are
differentially expressed between primary and metastatic tumors
and also predict overall survival in two independent datasets in
primary tumors. We started with the 87 genes that are the most
differentially regulated (p,0.05, FDR,0.25, average Fc.0.9,
Table S3). Using a scoring system similar to Kang et al. [11,13,22],
genes were initially evaluated using the Cox proportional hazards
model to determine if they are associated with survival in the
TCGA Affymetrix U133A microarray data. TCGA data evaluat-
ed only primary tumors. For genes expressed higher in metastases
compared to primary tumors, a point was assigned when the
expression was higher than the median. For genes expressed lower
in metastases compared to primary tumors, a point was assigned
when the expression was lower than the median. After summing
the points, cases with higher scores, .3 points, constituted the
high score group and cases with # 3 points were classified as the
low score group in Kaplan-Meier analysis. Six of the twelve genes
significantly distinguish high and low risk patients in three datasets:
TCGA Affymetrix U133A microarrays, TCGA Agilent Custom
244K microarrays and Affymetrix U133 Plus 2 microarrays from
the Australian Oncology Group [23,24] (Figure 2A). We find that
the two TCGA microarray platforms and decided to keep them
separate to identify transcripts associated with survival in each
dataset independently. These same six genes separate primary and
metastatic tumors by hierarchical clustering with good specificity
(Figure 2B). As another test of the six gene metastatic expression
signature, we tested its ability to classify patients based on
progression-free survival (PFS). Figure 2C shows the six gene
signature can distinguish high and low risk patients based on PFS.
Figure 1. Metastases are more proliferative and include less apoptotic cells than matched primary tumors. A. GSEA enrichment plot
suggests Reactome G2/M cell cycle checkpoints including Chek1, CCNB2, and BUB1 are expressed higher in primary tumors. B. Representative
immunohistochemical staining of Ki-67 from three cases suggest higher Ki-67 staining in omental metastases. C. Box plot of the percent cells with
positive Ki-67 staining. Paired t-test suggests significant differences between omental metastases and primary tumors from 19 cases. D. qPCR
validation of cell cycle checkpoints. Note that genes with significant .1.8 fold changes in the array validate in those same tumors by qPCR. Genes
with small expression changes measured by either the array or qPCR may be noisy in those tumors. E. GSEA enrichment plot suggests that negative
regulators of apoptosis are up-regulated in metastases. F. TUNEL staining of two representative cases shows increased TUNEL signal in metastases. G.
Box plot of the percent of cancer cells as determined by H&E staining with positive TUNEL staining. Paired t-test suggests significance.
doi:10.1371/journal.pone.0094476.g001
Ovarian Metastases Differ from Primary Tumors
PLOS ONE | www.plosone.org 4 April 2014 | Volume 9 | Issue 4 | e94476
Ovarian Metastases Differ from Primary Tumors
PLOS ONE | www.plosone.org 5 April 2014 | Volume 9 | Issue 4 | e94476
To further test the ability of the six gene classifier to distinguish
high and low risk patients, we evaluated the relationship of the
metastatic gene signature with residual disease. Residual disease is
associated with overall survival [4–6,25,26], with low survival for
patients with higher levels of macroscopic residual disease after
debulking surgery. However, patients considered to have no
residual disease after debulking surgery have an intermediate level
of survival. Patients with no observable residual disease, may then
presumably be subject to the innate aggressiveness of the disease
and response to chemotherapy, and not other variables such as the
location of the tumor and the ability to remove tumors surgically.
The six gene signature separates the high and low risk patients
with no macro-disease across all datasets very robustly (Fig. 2D).
The six gene signature does not separate high and low risk patients
with some residual disease as the effects of residual disease
apparently supersede the signature’s ability to detect aggressive
disease in the survival data. These observations suggest that the six
gene signature identifies primary tumors that are the most
aggressive.
Recent studies have suggested that there are many gene lists that
are strong predictors, even across multiple datasets [7,8,27]. To
determine if the six gene classifier is unique, or if there are multiple
combinations of six expressed genes that can distinguish high and
low risk patients, we evaluated .10,000 random sets of six genes
in the Affymetrix TCGA data. We find that using the same
parameters, that very few random gene lists of equivalent size are
predictors (Table 1). Thus, the metastatic gene list is among the
most significant possible combinations of six genes able to classify
patients in these datasets.
The six genes in the metastatic expression signature are shown
in Table 2. IL7R is highly expressed in T-cells and thus may be
associated with infiltrating T-cells, whose presence is higher in
many of the metastatic tumors in our study as indicated by higher
expression of other T-cell markers such as CD3 (data not shown).
Infiltrating immune cells in primary ovarian tumors are associated
with a metastatic phenotype and poor survival [9,28–31]. The
other five genes in the metastatic expression signature have not
been directly linked with ovarian cancer to date.
Genetically diverse cancer cells establish omental lesions
with similar phenotypes
To determine if copy number aberrations contribute to the
recurring gene expression changes, we evaluated DNA copy
number from 12 matched primary and omental metastases using
Agilent 180K CGH microarrays (Figure 3A). We performed
hierarchical clustering to investigate the relationship among 24
tumors from 12 patients based on their genomic alterations. These
data suggest that 8/12 primary-met pairs are more genetically
similar to each other than the other tumors, consistent with a
clonal expansion model [2,23] and patient specific evolutionary
trajectories [32]. Notably, almost every region of the genome is
represented in the cumulative spectrum of CNAs observed in the
collection of tumors, consistent with the known extensive genomic
instability of EOC [3,33] (Figure S4). Many CNAs are similar
between the primary and metastatic tumor, as suggested by
hierarchical clustering, however, notable differences are observed
in each patient suggesting the metastases are genetically distinct
from the primary tumor (Figure 3B).
Metastatic specific CNAs may indicate DNA copy number
changes that are necessary to establish metastases. To determine if
any metastatic specific CNAs are recurring, which may indicate
functional importance, segmented regions were mapped to genes
and a log2 ratio score for each gene was calculated. Genes in
amplified or copy loss regions with high or low expression were
selected. We observe one amplified gene, ERBB2, unique to
metastases and four genes uniquely amplified in primary tumors,
and not in omental lesions, in at least two patients where the
expression and copy number are correlated (Pearson.0.7)
(PDCD10, ZNF507, DTNA, AMN1). Each of these genes has
lower expression in all metastases, consistent with the role of copy
number in modulating expression. However, a recent study
examining ERBB2 expression and amplification, did not detect
noticeable differences between primary and omental metastases,
perhaps because of significant intratumoral heterogeneity [14,34].
These data suggest that few, if any, specific CNAs, unique to
metastases, are providing a selective advantage to establish
metastases in the major clone in the omental lesions. Alternatively,
the primary and metastatic tumors may be so heterogeneous that
they are not dominated by a single clone detectable in bulk tumor
samples. Together, these observations suggest that gene expression
Figure 2. Six gene metastasis signature distinguishes aggressive disease in patients and primary and metastatic tumors. A. Red
dotted lines indicate high risk group and the green line indicates the low risk group. For each patient’s tumor, a point was given for each metastasis
gene for which higher than median expression was associated with longer survival, and vice versa. Tumors with more than three points were
classified as high risk. Only patients who were treated with platinum or taxane chemotherapy were included. Two microarray platforms from TCGA
were evaluated (Affymetrix U133A and the Agilent Custom 244K). A second independent dataset on Affymetrix U133 Plus 2 microarrays from the
Australian Oncology group was also evaluated [18,24]. The median survival is shown with 95% confidence levels in parentheses. B. Hierarchical
clustering of the six gene metastasis signature separates the primary and metastatic tumors. Red indicates higher and blue lower expression. C. The
six gene metastatic signature distinguishes more aggressive disease using time to progression as a metric. D. The six gene signature predicts survival
for cases with no residual disease. Cases in each dataset with no macro disease after surgery were gathered and evaluated for overall survival.
doi:10.1371/journal.pone.0094476.g002
Table 1. Specificity of metastatic six gene signature.
Dataset P-value of 6 gene signature P-value relative to random sets
Affymetrix TCGA 0.004 0.001 (n = 10,729)
Agilent TCGA 0.0002 0.0008 (n = 10,054)
Australia 0.006 0.0025 (n = 10,000)
P-values are calculated by determining the number of random gene sets with lower p-values than the metastatic gene signature using the log-rank test of Kaplan Meier
analysis divided by the number of random sets tested as indicated in parentheses.
doi:10.1371/journal.pone.0094476.t001
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may be more indicative of the key features for development of
aggressive of ovarian cancer, than distinct genetic changes, or
selection of specific clones.
Discussion
Our key findings show that metastatic and primary tumors have
different expression profiles reflecting their proliferation and
apoptosis status. On the other hand, copy number analysis did
not reveal recurrent genetic changes in this cohort, suggesting that
the dominant clone in metastases may differ from the primary
tumor, or that these tumors have high intratumoral heterogeneity.
The expression changes indicative of aggressive disease between
primary tumors and omental lesions are common and important
for disease progression. Importantly, genes differentially expressed
between primary tumors and omental lesions identify a predictive
expression signature of patient outcome, suggesting the functional
importance of these genes in metastasis and disease progression.
Table 2. List of genes in six gene metastatic signature.
Gene Refseq ID Gene Name Function
CALB2 NM_001740 Calbindin 2 Cell junction, calcium binding
CYP1B1 NM_000104 Cytochrome P450, family 1, subfamily B,
polypeptide 1
Cholesterol and steroid metabolism
EFTUD1 NM_024580 Elongation factor Tu, GTP binding domain
containing 1
Translation elongation factor
IL7R NM_002185 Interleukin 7 receptor Plays a critical role in the V(D)J recombination during lymphocyte
development.
RARRES2 NM_000362 Retinoic acid receptor responder 2 Initiates chemotaxis via the ChemR23 G protein-coupled seven-
transmembrane domain ligand.
TIMP3 NM_000362 TIMP metallopeptidase inhibitor 3 matrix metalloproteinase inhibitor
doi:10.1371/journal.pone.0094476.t002
Figure 3. Hierarchical clustering of copy number aberrations and mRNA expression. A. Most patients cluster by their copy number
aberrations (CNAs). The circles indicate matched pairs of primary and metastatic tumors that cluster together with similar patterns of CNAs. B.
Representative heat maps of the copy number data from two cases. Many CNAs are found in both primary and metastatic tumors.
doi:10.1371/journal.pone.0094476.g003
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Together, these observations support the idea that ovarian
primary tumors encode significant metastatic potential.
Some studies suggest ovarian primary and metastatic tumors are
very similar by expression analysis [4,6,35], while others suggest
they differ [15,16]. We conclude that these tumors differ in key
features as supported by GSEA pathway analysis, IHC of Ki-67,
apoptosis analysis, and the identification of the six gene expression
signature. Our approach differs from past studies because of the
application of GSEA, which does not consider arbitrary thresholds
to identify differentially expressed pathways [17], leading to
increased sensitivity. Second, we validate the GSEA analysis
predictions with Ki-67 immunohistochemistry and TUNEL
staining in the tested cases and an extended set of cases. Third,
we identify a six gene signature that separates primary and
metastatic tumors and identifies aggressive disease in two
independent primary tumor datasets. Together, these observations
support the conclusion that omental metastases have significantly
different expression profiles than primary ovarian tumors, and
these expression differences identify key features of aggressive
disease. Importantly, these data may help explain why omental
metastases are aggressive as they are more proliferative and are
more resistant to cell death than primary tumors, similar to cancer
cells in 3D culture environments or cells that have survived
detached in culture for a prolonged period. These observations are
consistent with the concept that disseminating cancer cells can
become more anti-apoptotic during metastasis [9,36,37]. Future
examination of larger patient cohorts to test if omental metastatic
specific changes indicate patient survival better than primary
tumors can help address these questions.
For many of the identified networks, we cannot strongly
conclude that the expression changes are due to adaptation of the
cancer cells or changes in the type and number of infiltrating cells.
Our evaluation by immunohistochemistry and correlation of
expression with Ki-67 signal does suggest that many of the
expression changes originate from cancer cells. Nonetheless, some
signal from infiltrating cells is present as evidenced by increased
expression of CD3 and IL7R in metastases that likely originate
from T cells. Because most large tumor characterization studies
also use the same criteria as applied here to collect .70% bulk
tumor, we were able to derive a predictive expression signature
that includes genes that likely originate from both cancer and
infiltrating cells.
The scoring system used here is flexible, as contributions from
different sets of genes can be used to identify the high-risk patients
for a general metastatic signature, allowing for some variation in
the tumors in individual patients. We propose that the full 87 gene
signature can be used as an initial set of genes to identify and to
refine a metastatic gene signature that can distinguish primary and
metastatic tumors as well as high risk patients in a wide-range of
survival data. We find that random selections of gene sets rarely
are associated with survival unlike the situation in breast cancer
(Table 1). This could be because proliferation and the cell cycle
based signatures do not predict survival in ovarian cancer as well
as they do in breast cancer [6,27,38].
These data suggest that a variety of cancer genomes can lead to
the same metastatic phenotype, defined by common expression
patterns. We observe many common expression changes between
primary and metastatic tumors, but no common enrichment of
specific copy number changes. The diversity of genomes between
primary and metastatic tumors in this cohort may be due to
intratumoral or interpatient genetic heterogeneity or both. The
diversity observed in this study is consistent with sequencing
analysis of primary and metastatic ovarian tumors that found
significant patient heterogeneity [32]. Ovarian cancer is a very
genetically heterogeneous disease, but the phenotypes needed to
metastasize appear to more common suggesting that targeting
phenotypes may treat large patient populations than most genetic
based approaches.
These observations highlight the changing state of ovarian
tumors that should be considered as various treatment options are
developed. Our data support the hypothesis that metastases are
distinguishable from primary tumors, likely influenced by the
omental microenvironment. This hypothesis suggests that deeper
examination of metastases is necessary to treat the disease, as
distinct pathways may be activated in metastases.
Understanding the molecular features unique to omental lesions
may be critical to understand and to improve treatment of
advanced ovarian cancer. These data should inspire future studies
to address the function of these metastatic networks and how they
may be important in sustaining the tumors and driving further
metastasis. Future studies examining which signaling pathways or
transcription factors cause the observed expression changes will be
important to understand the regulation of these behaviors. Future
maturation of the clinical data and larger patient cohorts will also
likely provide more insights into the connections between
metastasis, drug response, and patient outcomes.
Supporting Information
Figure S1 Tumors are of ovarian origin and are serous
epithelial as indicated from examination of H&E and
cytokeratin staining. Representative H&E staining of two
representative cases. CA125 and cytokeratin staining of one case is
consistent with ovarian tumor origins.
(PPTX)
Figure S2 Microarray and qPCR measurements gener-
ally agree. qPCR validation of genes primary and metastatic
tumors from two cases. Not all these genes have q,0.1.
(PPTX)
Figure S3 Enriched pathways reveal common features
of metastases. GSEA enrichment plot suggests that WNT/b-
Catenin signaling from the Signaling Transduction database and
double strand break repair gene ontology are up-regulated in
metastases compared to primary tumors.
(PPTX)
Figure S4 Summary of all CNAs in all 12 cases. Most of
the genome is subject to copy number aberrations consistent with
extensive genomic instability of serous ovarian cancer. Green is
amplification, red is copy loss.
(PPTX)
Table S1 A. Cases used for mRNA microarrays. B. Cases used
for CGH microrrays. C. Cases used for Ki-67 and TUNEL
staining.
(XLSX)
Table S2 Primer sequences used for qPCR.
(XLSX)
Table S3 87 genes selected for survival analysis.
(XLSX)
Table S4 A. Kegg Gene Sets up-regulated in Mets. B. Kegg
Gene Sets down-regulated in Mets. C. Reactome Gene Sets up-
regulated in Mets. D. Reactome Gene Sets down-regulated
in Mets. E. Transcription factor target gene sets up-regulated in
Mets. F. Transcription factor target gene sets down-regulated in
Mets.
(XLSX)
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